Rani Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Rani Therapeutics Holdings's earnings have been declining at an average annual rate of -34.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 63.6% per year.
Key information
-34.5%
Earnings growth rate
-20.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -63.6% |
| Return on equity | -950.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Jul 16
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Mar 20Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Aug 08We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Feb 13Revenue & Expenses Breakdown
How Rani Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -28 | 24 | 27 |
| 30 Jun 24 | 0 | -31 | 25 | 33 |
| 31 Mar 24 | 0 | -33 | 26 | 37 |
| 31 Dec 23 | 0 | -34 | 26 | 40 |
| 30 Sep 23 | 0 | -36 | 28 | 42 |
| 30 Jun 23 | 0 | -34 | 28 | 40 |
| 31 Mar 23 | 0 | -33 | 27 | 39 |
| 31 Dec 22 | 0 | -31 | 27 | 37 |
| 30 Sep 22 | 0 | -27 | 26 | 34 |
| 30 Jun 22 | 0 | -22 | 34 | 36 |
| 31 Mar 22 | 2 | -15 | 31 | 31 |
| 31 Dec 21 | 3 | -8 | 28 | 26 |
| 30 Sep 21 | 3 | -3 | 24 | 22 |
| 30 Jun 21 | 3 | 0 | 9 | 13 |
| 31 Mar 21 | 1 | 5 | 6 | 11 |
| 31 Dec 20 | 0 | 0 | 5 | 12 |
| 31 Dec 19 | 1 | -27 | 3 | 25 |
Quality Earnings: RANI is currently unprofitable.
Growing Profit Margin: RANI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RANI is unprofitable, and losses have increased over the past 5 years at a rate of 34.5% per year.
Accelerating Growth: Unable to compare RANI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RANI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: RANI has a negative Return on Equity (-950.94%), as it is currently unprofitable.